- Opinion
- [Reporter’s View] Please wait for policies to take effect
- by Lee, Tak-Sun Jun 1, 2023 05:39am
- The government is pushing to reform the drug pricing system to reduce the number of generics. It is said that the authorities are considering a plan that does not grant the premium price allowed for innovative pharmaceuticals to generics that exceed a certain number. The analysis is that the government's decision to regulate the number of
- Company
- Keytruda is expected to enter the domestic market
- by Eo, Yun-Ho Jun 1, 2023 05:38am
- Keytruda, an immuno-oncology drug, is aiming to expand indications for early lung cancer in Korea. According to the related industry, MSD Korea is a non-small adult stage 1B (tumor size of 4 cm or more), stage 2 or 3A after surgical excision of the PD-1 inhibitor Keytruda (pembrolizumab) and use of a platinum complex chemotherapy agent. A po
- Company
- Lyumjev can be prescribed at general hospitals
- by Eo, Yun-Ho May 31, 2023 05:37am
- According to related industries, Korea Lily's Lyumjev has passed the Drug Committee of medical institutions such as Samsung Seoul Hospital, Seoul National University Hospital, Seoul Asan Hospital, Gangnam Severance Hospital, and Seoul National University Bundang Hospital. This drug was approved in Korea in December 2021, and insurance ben
- Policy
- Vemlidy IMDs compete with lower price
- by Lee, Tak-Sun May 31, 2023 05:37am
- The latecomers of the hepatitis B treatment Vemlidy that entered the market this year are focusing on their price competitiveness to occupy more shares of the market. Companies that had already reduced their price upon entry are also seemingly holding in check their competitors' prices. According to industry sources on the 29th, Daewoo
- Company
- Samsung Bioepis, Soliris biosimilar approved in Europe
- by Chon, Seung-Hyun May 31, 2023 05:36am
- Samsung Bioepis announced on the 30th that it has obtained item permission from EC for Episcli, a biosimilar of Soliris, a treatment for rare diseases. On March 30, after obtaining a positive opinion for sales approval from CHMP under the EMA, the final approval was obtained two months later. Episcli is the first biopharmaceutical in hematolo
- Company
- Verzenio prescribing guideline recommendations
- by Eo, Yun-Ho May 31, 2023 05:36am
- Verzenio is expected to be used in early breast cancer patients with a high risk of recurrence even after surgery. Looking at the recently published domestic and international breast cancer treatment guidelines, the CDK4/6 inhibitor Verzenio was recommended based on a high level of evidence as adjuvant therapy after surgery for patients with
- Company
- 2 K-biosimilars are approved in the US and Europe per year
- by Chon, Seung-Hyun May 31, 2023 05:36am
- Biosimilar drugs that were developed in Korea are accelerating entry into the global market. Over the past decade, 13 and 10 biosimilars developed by Celltrion and Samsung Bioepis have been approved in Europe and the US, respectively. After Celltrion's Remsima received EMA approval in 2013, an average of 2 biosimilars have passed European and US
- Company
- Sales of Keytruda rose 117%
- by Chon, Seung-Hyun May 30, 2023 06:59pm
- Immuno-oncology drug Keytruda continued its high-altitude march in the domestic pharmaceutical market. Last year, Health Insurance 2 sales more than doubled as the number of recipients of the leading water-based benefits expanded for 13 consecutive quarters since the first quarter of 2020. Keytruda further strengthened its solo system by more th
- Product
- Prof Seong-Hoon Kim's research team reveals the mechanism
- by Jung, Heung-Jun May 30, 2023 05:33am
- It is expected that domestic researchers will speed up the development of a new fibrosis treatment by uncovering the mechanism of action of Bersiporocin, which is being developed as a treatment for idiopathic pulmonary fibrosis. Yonsei University Professor Seong-Hoon Kim and Dr. Ina Yoon's research team conducted joint research with Professo
- Policy
- Lowest price of dapagliflozin set at 30% of original price
- by Lee, Tak-Sun May 30, 2023 05:33am
- In 2 months after the entry of generics in the market, the price difference between the original diabetes treatment Forxiga Tab (Dapagliflozin propanediol hydrate) and its generics has become one-third. This is because in April last year when many Forxiga generics were listed at once to exceed 20, the insurance price ceiling dropped signi
